South Korea
· Delayed Price · Currency is KRW Pharos iBio Statistics
Total Valuation
Pharos iBio has a market cap or net worth of KRW 77.42 billion. The enterprise value is 61.87 billion.
| Market Cap | 77.42B |
| Enterprise Value | 61.87B |
Important Dates
The last earnings date was Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharos iBio has 12.95 million shares outstanding. The number of shares has increased by 6.81% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 12.95M |
| Shares Change (YoY) | +6.81% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 33.45% |
| Owned by Institutions (%) | 17.66% |
| Float | 8.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 4.16 |
| P/TBV Ratio | 4.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.86 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.18 |
Financial Position
The company has a current ratio of 16.70, with a Debt / Equity ratio of 0.01.
| Current Ratio | 16.70 |
| Quick Ratio | 16.25 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -2,095.64 |
Financial Efficiency
Return on equity (ROE) is -44.97% and return on invested capital (ROIC) is -33.24%.
| Return on Equity (ROE) | -44.97% |
| Return on Assets (ROA) | -31.94% |
| Return on Invested Capital (ROIC) | -33.24% |
| Return on Capital Employed (ROCE) | -67.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.88% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -68.88% |
| 50-Day Moving Average | 7,887.40 |
| 200-Day Moving Average | 9,447.15 |
| Relative Strength Index (RSI) | 31.61 |
| Average Volume (20 Days) | 78,975 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -25.93M |
| Operating Income | -12.60B |
| Pretax Income | -10.56B |
| Net Income | -10.56B |
| EBITDA | -11.80B |
| EBIT | -12.60B |
| Earnings Per Share (EPS) | -817.00 |
Balance Sheet
The company has 15.67 billion in cash and 123.72 million in debt, giving a net cash position of 15.54 billion or 1,200.70 per share.
| Cash & Cash Equivalents | 15.67B |
| Total Debt | 123.72M |
| Net Cash | 15.54B |
| Net Cash Per Share | 1,200.70 |
| Equity (Book Value) | 18.61B |
| Book Value Per Share | 1,437.86 |
| Working Capital | 15.28B |
Cash Flow
In the last 12 months, operating cash flow was -9.33 billion and capital expenditures -676.78 million, giving a free cash flow of -10.00 billion.
| Operating Cash Flow | -9.33B |
| Capital Expenditures | -676.78M |
| Free Cash Flow | -10.00B |
| FCF Per Share | -772.76 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pharos iBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.81% |
| Shareholder Yield | -6.81% |
| Earnings Yield | -13.64% |
| FCF Yield | -12.92% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |